Checkpoint Inhibitor-Induced Pneumonitis: Incidence and Management-Reference-Cited by-同舟云学术

Checkpoint Inhibitor-Induced Pneumonitis: Incidence and Management

Published:2023-07-05 Issue:3 Volume:12 Page:134-143
ISSN:2199-2428
Container-title:Current Pulmonology Reports
language:en
Short-container-title:Curr Pulmonol Rep

Author:

Yuan Chaofan,Gada Kunal,Desai Alpa G.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

https://link.springer.com/content/pdf/10.1007/s13665-023-00314-z.pdf

Reference77 articles.

1. American Cancer Society. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html. Accessed 1 May 2023.

2. Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008–19.

3. Haanen JBAG, Thienen H van, Blank CU. Toxicity patterns with immunomodulating antibodies and their combinations. Semi Oncol [Internet]. 2015 [cited 2023 Mar 3];42(3):423–8. Available from: https://doi.org/10.1053/j.seminoncol.2015.02.011.

4. Zhang H, Dutta P, Liu J, Sabri N, Song Y, Li WX, et al. Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer. J Cell Mol Med [Internet]. 2019 [cited 2023 Mar 3];23(1):535–42. Available from: Available from: https://doi.org/10.1111/jcmm.13956.

5. Kalisz KR, Ramaiya NH, Laukamp KR, Gupta A. Immune checkpoint inhibitor therapy–related pneumonitis: patterns and management. RadioGraphics [Internet]. 2019 [cited 2023 Mar 26];39(7):1923–37. Available from: https://doi.org/10.1148/rg.2019190036.